The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
 
Jordan Gauthier
Consulting or Advisory Role - EUSA Pharma; JMP Securities; Multerra Bio
Travel, Accommodations, Expenses - European Society for Blood and Marrow Transplantation (EBMT); International Academy of Clinical Hematology; iwCAR-T
 
Aisling Cearley
No Relationships to Disclose
 
Paula Perkins
No Relationships to Disclose
 
Angela Kirk
No Relationships to Disclose
 
Mazyar Shadman
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Genentech; Innate Pharma; Kite, a Gilead company; MorphoSys; Pharmacyclics; Sound Biologics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Staci Williamson
No Relationships to Disclose
 
Jessie Myers
No Relationships to Disclose
 
Andy I. Chen
Consulting or Advisory Role - Mesoblast; MorphoSys
Research Funding - Fate Therapeutics
 
Sarah Nagle
No Relationships to Disclose
 
Brandon M. Hayes-Lattin
Research Funding - Novartis (Inst)
 
Levanto Gershon Schachter
No Relationships to Disclose
 
David G. Maloney
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech/Roche; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Legend Biotech; MorphoSys; Novartis; Pharmacyclics
Consulting or Advisory Role - A2 Biotherapeutics
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
Cameron John Turtle
Stock and Other Ownership Interests - ArsenalBio; Caribou Biosciences; Eureka Therapeutics; Myeloid Therapeutics; Precision Biosciences
Consulting or Advisory Role - Alimera Sciences; Aptevo Therapeutics; ArsenalBio; Asher Biotherapeutics; AstraZeneca/MedImmune; Caribou Biosciences; Century Therapeutics; Genentech; Humanigen; Kite/Gilead; Myeloid Therapeutics; Nektar; Novartis; PACT Pharma; Precision Biosciences; T-CURX
Research Funding - AstraZeneca/MedImmune; Juno Therapeutics; Nektar
Patents, Royalties, Other Intellectual Property - Three patents licensed or pending.
 
Mohamed Lotfy Sorror
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - Jazz Pharmaceuticals
 
Richard T. Maziarz
Honoraria - Novartis; omeros; PACT Pharmaceuticals
Consulting or Advisory Role - Artiva; bms; incyte; Intellia Therapeutics; Kite, a Gilead company; Novartis
Patents, Royalties, Other Intellectual Property - ATHERSYS, INC shared patent re: use of mesenchymal stromal cells for treatment of GVHD
Travel, Accommodations, Expenses - Incyte; Kite, a Gilead company; Novartis